We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
- Authors
Strati, Paolo; Wierda, William; Burger, Jan; Ferrajoli, Alessandra; Tam, Constantine; Lerner, Susan; Keating, Michael J; O'Brien, Susan
- Abstract
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with chronic lymphocytic leukemia (CLL). However, its therapeutic power is counterbalanced by significant hematologic toxicity. Persistent and new-onset cytopenia after the completion of FCR raise concern about disease recurrence, the development of therapy-related myeloid malignancies (TRMM), and infections.
- Publication
Cancer, 2013, Vol 119, Issue 21, p3805
- ISSN
1097-0142
- Publication type
Journal Article
- DOI
10.1002/cncr.28318